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Abstract
Rigorous organization and quality control (QC) are necessary to facilitate successful genome-wide
association meta-analyses (GWAMAs) of statistics aggregated across multiple genome-wide
association studies. This protocol provides guidelines for [1] organizational aspects of GWAMAs,
and for [2] QC at the study file level, the meta-level across studies, and the meta-analysis output
level. Real–world examples highlight issues experienced and solutions developed by the GIANT
Consortium that has conducted meta-analyses including data from 125 studies comprising more
than 330,000 individuals. We provide a general protocol for conducting GWAMAs and carrying
out QC to minimize errors and to guarantee maximum use of the data. We also include details for
use of a powerful and flexible software package called EasyQC. For consortia of comparable size
to the GIANT consortium, the present protocol takes a minimum of about 10 months to complete.
INTRODUCTION
Background
The genome-wide association (GWA) study approach has been extremely successful in
pinpointing association of common genetic variants with diseases or disease-related
quantitative phenotypes1, 2. However, given the small sizes of the expected effect under a
polygenic model, individual GWA studies are generally too small to provide the necessary
power to detect single nucleotide polymorphism (SNP) associations, while accounting for
the multiple number of independent tests. Therefore, the genetics community has widely
adopted the approach of combining summary statistics from multiple GWAS into a single
meta-analysis to increase the statistical power of the analysis by augmenting the effective
sample size3, 4. These GWAMAs collate data from GWA studies conducted around the
world and thus require an enormous organizational effort to ensure effective
communication, standardization of analytical procedures, and coordination at both the study-
specific level and the meta-analysis level, followed by rigorous quality control (QC) during
the meta-analysis process. Although a QC protocol for individual GWA studies has been
described before5, a comprehensive protocol describing state-of-the-art procedures to
conduct and perform QC of large-scale GWAMAs is currently lacking.
The typical GWAMA approach is to design a standardized analysis plan centrally and share
it with the individual study partners who will perform the GWAs according to the
designated analysis plan. More specifically, the study analysts conduct study-specific GWA
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QC for each SNP, and impute the genome-wide SNP array data. Next, they compute
association statistics for each SNP, including effect size estimates with standard errors (or
odds ratios with corresponding confidence intervals for case-control samples), allele
frequencies, sample size, and P-values, and provide these summary statistics to the meta-
analyses centers. Typically, data on the individual participants, alongside phenotype and
genome-wide SNP genotype information, are not shared to guarantee anonymity of study
participants and to conform to strict data-sharing policies. The unavailability of individual
participant data at the meta-analyses centers creates unique analytical challenges for QC,
requiring specific statistical and graphical tools to track errors in the study-specific analysis
from the available aggregated data.
Study-specific data issues that need to be detected at the meta-analysis stage include file
naming errors (e.g. female-specific files labeled as male-specific), erroneous SNP genotype
data (e.g. flipped alleles, duplicate SNPs, bad imputation quality), and association issues
stemming from incorrect analysis models (e.g. improper model adjustments, population
stratification, and unaccounted relatedness of individuals). Although some errors impede the
meta-analysis (e.g. file formatting errors), others (e.g. incorrect trait transformations and
flipped alleles) limit the full contribution of a study to the meta-analysis and thus lower the
power of the meta-analysis or inflate the number of false positives (type I errors, e.g.
unaccounted population stratification). Issues that inflate the number of type I errors should
be avoided with higher priority than issues that increase the number of false negatives (type
II errors), which negatively affect the statistical power of the meta-analysis. False positives
could set researchers onto the wrong track, leading them to spend time and money on
misguided follow-up studies, whereas missed genetic signals can be expected to emerge in a
following, larger GWAMA.
A typical GWAMA involves two stages: (i) a discovery stage, in which meta-analyzed
GWA data are used to select promising variants, and (ii) a follow-up stage, in which
analyses are performed on data derived either from de novo genotyping or from existing
genome-wide data (in silico). This protocol focuses on the discovery stage. Although in
silico follow-up data can generally be treated similarly to discovery GWA data for QC
purposes, de novo genotyped data needs to be checked with a particular focus on SNP strand
issues, call-rate, Hardy-Weinberg equilibrium (HWE)5 or other technical steps related to the
particular genotyping technology applied.
In recent years, GWAMAs have become more and more complex. Firstly, GWAMAs can
extend from simple analysis models to more complex models including stratified6 and
interaction7, 8 analyses. Secondly, beyond imputed genome-wide SNP arrays, new custom-
designed arrays such as Metabochip9, Immunochip10, and Exomechip11 are increasingly
integrated into meta-analyses. Because of differing SNP densities, strand annotations, builds
of the genome, and the presence of low-frequency variants, data from such arrays require
additional processing and QC steps (also outlined in this protocol using the example of the
Metabochip). Finally, GWAMAs involve an ever-increasing number of studies. Up to a
hundred studies were involved in recent GWAMAs12–17, often involving 1,000 to 2,000
study-specific files. Increasing the scale and complexity of GWAMAs increases the
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likelihood of errors by study analysts and meta-analysts, underscoring the need for more
extensive and automated GWAMA QC procedures.
We present a pipeline model that provides GWAMA analysts with organizational
instruments, standard analysis practices, and statistical and graphical tools to carry out QC
and to conduct GWAMAs. The protocol is accompanied by an R package, EasyQC, a user-
friendly software that implements this GWAMA QC pipeline and is flexible to
accommodate additional and alternative steps.
Development of the protocol
Our protocol was developed by analysts from the GIANT Consortium, which is one of the
largest global collaborations to study complex traits and diseases, currently including up to
125 studies into the meta-analysis. Established in 2006, GIANT has accumulated a lot of
experience with GWAMAs. Four rounds of analyses have already been conducted, with
each round incorporating new studies and chip technologies. 13, 15, 18–20. Our work
illustrates the increasing complexity of GWAMAs: we deal with multiple phenotypes (e.g.
height, body mass index (BMI), waist-hip ratio (WHR), waist and hip circumference (WC
and HIP), the latter three also with adjustment for BMI (WHRadjBMI, WCadjBMI, HIPadjBMI),
and body fat percentage), multiple SNP platforms (genome-wide SNP and Metabochip
arrays), multiple analysis models (without and with adjustment for BMI, interaction with
smoking status and with physical activity, sex- and age- stratified analyses, and various
dichotomizations of the BMI distribution6, 21), including imputed and unimputed SNP data,
and an ever-increasing number of studies per meta-analysis (16 initially and up to 125 in the
current analyses). Our on-going analyses include more than 1,500 GWA input files,
necessitating an efficient QC pipeline. The size and experience of the GIANT Consortium
provides an ideal basis for the development of a GWAMA protocol. The protocol and tools
can readily be applied by other consortia using aggregated statistics for meta-analysis,
studying other quantitative traits and using other statistical models or other genotyping
platforms. We have incorporated all QC steps that proved to be helpful during our GIANT
work and have been known to be efficient in other consortia’s work. We have also
developed special tools to conduct meta-level QC and to handle the particularly large
number of files.
Limitations
Firstly, this protocol has been developed for human genomic data. Although some aspects
can be applied to non-human data, a detailed protocol for other species is beyond the scope
of the present protocol.
Secondly, even a perfect protocol for the meta-analysis of aggregated statistics cannot fully
compensate for not having access to individual participant data, which would guarantee
standardized QC and analyses across studies. Advantages and disadvantages of meta-
analyses using individual participant data are summarized in the “Comparison with other
approaches” section, below. However, ethically motivated restrictions to sharing genome-
wide genotype and phenotype data currently limit the realization of individual participant
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GWAMAs, which is the reason why the aggregated statistics GWAMA – as described here
– is the currently most widely applied approach.
Applications of the protocol
Generally, this protocol assumes that the study analysts have quality-controlled their study
data regarding phenotype and genotype as well as accounted for ethnicity, race and familial
relatedness. For these steps, there are standardized protocols available5. It also assumes that
they either have imputed their genome-wide SNP array data – ideally with a pre-specified
common reference panel – to ensure a common SNP panel across all studies, or that they
have data from an unimputed custom genotype array available.
This protocol specifically focuses on the discovery stage of a GWAMA, but can be readily
applied to the follow-up stage as well. Imputed in silico follow-up data can be treated in a
similar way as the here described imputed genome-wide SNP array data, non-imputed in
silico or de novo genotyped data can be treated like the Metabochip data regarding the
cleaning of call rate, HWE, and strand issues.
Although this protocol has been developed for quantitative phenotypes and HapMap
imputed or typed common autosomal genetic variants, it can be extended to 1000 Genomes
imputed variants, dichotomous phenotypes, rare variants, gene-environment interaction
(GxE) analyses and to sex chromosomal variants. A summary of directly applicable protocol
steps or steps requiring adaptation is given in Table 1. Since 1000 Genomes imputed data
extends to a larger SNP panel and includes structural variants (SV) and insertions or
deletions (indels), the allele coding and harmonization of marker names require special
consideration: (i) Additional allele codes (other than “A”,”C”,”G” or ”T”) are needed for
indels and SVs (e.g., “I” and “D” for insertions and deletions). (ii) To account for the fact
that some SVs and indels map to the same genomic position as SNPs, the identifier format
“chr<chromosome>:<position>” would introduce duplicates. Therefore, the identifier format
needs to be amended (e.g. to “chr<chromosome>:<position>:[snp|indel]”, which adds the
type to the format).
For dichotomous traits, the effective sample size needs to be computed by Neff=2/(1/Ncases +
1/Ncontrols), an expression that balances the number of cases with the number of controls.
Custom-array data require checks of genotype quality per case status. The analysis is usually
performed using logistic instead of linear regression providing beta estimates and standard
errors that enable the implementation of the same meta-analysis methods. The MAC cut-off
requires more consideration: It depends on the logistic-regression-based test used and on the
ratio between number of cases and controls22.
For rare and low-frequency variants more refined considerations regarding the minimal
sample size or the minimally acceptable MAC cut-off per file are required. The
comparability of the study frequencies with reference data such as HapMap or 1000
Genomes is of limited use as Exomechip or custom-made chips focusing on rare variants
and low-frequency tend to include novel or population-specific variants. Often, the single-
variant analyses are complemented by gene-based burden tests requiring special
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consideration. For single-variant analyses, most of the protocol steps described herein are
directly applicable.
Results for analyses models that include an interaction term can also be quality-controlled
by this protocol. The main SNP effect estimates can be treated like the SNP effects without
interaction. The interaction effect estimates need to be cleaned and meta-analyzed in
addition. This objective can be achieved in the same fashion as the main effect estimates or
implementing alternate methods23. As the analysis of the interaction between SNP and the
environment is more and more included into GWAMA efforts, this approach will be of
increased importance.
Analyses with sex-chromosomal variants require some special considerations, in particular
in men. We assume that study partners have quality-controlled their data regarding rare
gonosomal aberrations (X0, XXX, XYY). The potential errors in coding variants in men
include differences in the coding of X-chromosomal variants (either 0|1 or 0|2 for men) or
erroneous coding of pseudo-autosomal variants (should be 0|1|2). Separating the QC by X-,
Y-, and pseudo-autosomal variants in men can be grasped by deflated or inflated beta-
estimates (and thus standard errors) in the SE-N (i.e., inverse of the median standard error
versus the square root of the sample size) plot. Generally, sex-chromosomal variants should
be cleaned and analyzed in men and women separately.
Comparison with other approaches
Over the past six years, more than 100 large phenotype-driven consortia of genetic
association studies have emerged1. Most of these consortia follow a similar framework for
QC and data ‘sanity checks’ as outlined here24.
Some consortia, such as the Uric Acid (UA) Consortium, follow slightly modified
procedures, whereby study-specific QC metrics, generated by GWAStoolbox25, were
collected next to summary level association statistics26. This approach enables the easy
detection of basic data problems even before the results are shared, but at the same time it
poses an extra burden on the analysts, and its implementation does not help the necessity of
meta-level checks. The Chronic Kidney Disease Genetics (CKDGen) Consortium omits
filtering data based on poor imputation quality27, whereas most consortia, including GIANT,
delete badly imputed variants from the meta-analysis (see below).
Whereas most GWAMAs meta-analyze study-specific statistics, where study analysts have
provided GWA results to the meta-analysis center, the Psychiatric Genomic Consortium
(PGC) conducts a meta-analysis of individual participant data, as both the individual-level
genotype and phenotype data of all participating studies are deposited centrally28. This
approach has the following advantages: 1) central quality control: genotype and phenotype
data can be modeled and quality-controlled centrally, eliminating the need for subsequent
troubleshooting; 2) standardized study-specific analyses: fewer analysts are involved and the
utilization of the same imputation and association analysis software is guaranteed; and 3)
flexibility: more complex and comprehensive statistical analyses can be conducted without
burdening a large number of study analysts. However, our GWAMA approach has also
advantages compared to the meta-analysis of individual participant data: 1) gathering
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experts: the more analysts are involved, the more the network can profit from the
accumulated expertise; 2) local know-how: local study analysts know their study better than
a central team of meta-analysts; and 3) compliance: ethically motivated restrictions may
limit the sharing of genome-wide genotype and phenotype data due to the risk of participant
identification inhibit the study contribution29–31. In summary, the framework presented in
this protocol reflects the currently most widely applied GWAMA conduct and QC approach.
Experimental Design
Organizational aspects of the conduct of a typical GWAMA (Steps 1–6)
The typical GWAMA starts with the setting up of logistics aimed at achieving a smooth
communication between participating partners, analysts, and principal investigators, limiting
the burden for study analysts, so as to ensure a timely delivery of results to the meta-analysis
team.
Once study partners have been identified, general rules for the collaboration can be issued in
a ‘memorandum of understanding’ to set out the guidelines of confidentiality, data access,
publication of results, and authorship. Subsequently, collaborators and analysts are invited to
join task groups and regular teleconference calls.
An analysis plan is designed centrally by the meta-analysts to describe the standardized
analyses to be performed ‘locally’ and to detail phenotype transformation (e.g. to deal with
non-normal phenotype distributions and to enable comparability across studies), genotype
handling, imputation requirements, and association analysis methods (statistical model,
adjustment, stratification). Where possible and reasonable, software scripts are provided to
every participating study group to minimize the potential of errors and to alleviate the
analysis burden for the study analyst. The analysis plan also defines the required aggregated
association statistics (e.g. SNP identifier, effect allele, allele frequency, beta estimate,
standard error, sample size, call rate or imputation quality, and P-value) and details the
format in which they need to be submitted (see Box 1). In the design of the analysis plan,
whether or not to provide detailed and lengthy guidelines, possibly including even software
codes, needs to be weighed against providing a short and comprehensive — but potentially
more error-prone — description. The less standard the requested analyses, the more details
need to be provided. A general analysis plan format cannot be provided, but the GIANT
analysis plan can serve as an example that has worked and has been improved through
several rounds of meta-analyses (Supplementary Manual). The analysis plan is discussed
with the study collaborators and then sent out to each study analyst, including a deadline and
server access details for data upload.
When data from all studies have been uploaded to a password-secured file server, a data
freeze ensures the integrity of the data for all meta-analysts, regardless of download time
(Supplementary Figure 1).
The complete turnaround time for consortia comparable in size to GIANT (>100 studies in
meta-analysis) is, at minimum, around 10 months: 2 months to set up the logistics and to
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develop the analysis plan, 2 months to collect the data after the analysis plan has been sent
out, and 6 months to perform QC and meta-analysis.
QC—The workflow involves three QC steps: file-level QC (Steps 7–18), meta-level QC
(Steps 19–26), and meta-analysis QC (Steps 29–32). The file-level QC tackles formatting
issues that can be checked independently on each study file. In the meta-level QC, the study-
specific statistics are compared across studies or with reference panels to detect errors in the
analyses that cannot be identified by examining the study files individually. The meta-
analysis QC works on the level of already aggregated meta-analysis results and helps to
remove or flag suspicious SNP results. The workflow and the three QC steps are presented
in Figure 1.
File-level QC (Steps 7–18): This stage involves ‘cleaning’ (deleting poor quality data) and
‘checking’ (providing summaries to judge data quality) data. Thresholds for what data to
remove are typically defined a priori (e.g. by this protocol). Although data checking should
ascertain that there are no issues left, it often reveals further issues, which require re-
cleaning and re-checking. A few QC iterations may be needed before all files are fully
cleaned and ready for meta-analyses. Which SNPs or study files are to be removed depends
on how much the improvement in data quality weighs against loss of data. On the one hand,
the stricter the QC, the more SNPs or study files are removed and thus the lower the
coverage or sample size (and thus power). On the other hand, the more relaxed the QC
requirements, the larger the coverage and sample size at the expense of data quality, which
also decreases power.
Clearly, monomorphic SNPs or SNPs with missing (e.g. missing P-value, beta estimate, or
alleles) or nonsensical information (e.g. alleles other than A, C, G, or T, P-values or allele
frequencies >1 or <0, or standard errors ≤0, infinite beta estimates or standard errors) are of
no help to the meta-analysis and need to be removed. Systematically missing values or
errors can point towards analysis problems; thus, such data calls into question the
correctness of the data and should be discussed with the study analyst. A large number of
monomorphic SNPs can also point towards study-specific array problems.
If a study includes a low number of individual participants, its summary statistics can be
unstable (e.g. zero or infinite standard errors, zero P-Values or extremely large beta
estimates), which might drive the meta-analysis towards detecting false positives. This risk
pertains in particular to low-frequency variants. The detection of false positives due to the
low statistical power of the meta-analysis can be avoided by requiring a minimum sample
size per study and a minimum number of minor alleles contributing to a SNP for each
participating study. For example, in meta-analyses performed by the GIANT consortium,
SNPs were removed from the study file if the number of individuals informative for the SNP
was lower than 30 or the minor allele count was (MAC, computed as 2*MAF*N, with MAF
being the minor allele frequency) equal or less than 6.
Imputed genotype data is often filtered based on imputation quality. For example, in the
GIANT consortium, poorly imputed SNPs were removed according to a threshold that
depended on the imputation method and on the imputation quality metric (Table 2).
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Arguably, however, SNPs with poor imputation quality can be retained in the meta-
analysis27: on one hand, a badly imputed SNP can be considered a random, non-differential
error in the genotype (i.e. not systematically prioritizing one genotype and independent of
the phenotype) and thus it will not tend to create a false signal and, on the other hand, a
study with the SNP badly imputed will neither contribute to a true signal nor mask it.
Filtering poorly imputed SNPs has the advantage that no nonsensical results are unduly
decreasing the statistical significance of truly informative data.
Sex-chromosomal and autosomal SNPs require different genotype models and therefore are
often studied separately from each other. To focus on autosomal SNPs and consistent
genotype models across studies in its analyses the GIANT consortium has removed any sex-
chromosomal SNPs.
SNP identifiers often differ between arrays and/or imputation reference panels and,
therefore, often differ between studies. Their harmonization across studies is pivotal to the
meta-analysis. For example, a SNP that is assigned to two different SNP identifiers (e.g.
rs123 in half of the studies and rs17614680 in the other half) will appear as two different
SNPs in the meta-analysis output, with the total sample size split across the two SNPs; a true
signal might, therefore, be missed due to loss of statistical power. For HapMap imputed
studies, a unique SNP identifier can be generated by combining the SNP’s genetic positions
to generate the format “chr<chromosome>:<position>”. However for some arrays (e.g.
Metabochip) not all SNPs map to a standard reference panel. In such cases, the DNA probe
sequences need to be mapped to the reference genome build of interest to arrive at a
common chromosome and position, which can then be used to generate the SNP identifier.
This procedure will also remove SNPs that do not map uniquely to the genome. Maps with
unique SNP identifiers and genomic positions (for several different genome builds) for
several commercial arrays are freely available for download (see: http://www.well.ox.ac.uk/
~wrayner/strand/).
Meta-level QC (Steps 19–26): This stage consists in the cross-study comparison of
statistics to identify study-specific problems. This QC stage compensates for not having the
individual participant data of each study available to the meta-analyst. We recommend the
following plots to be included in the GWAMA QC protocol.
The SE-N plot (Steps 19–20): Several types of analytical problems can be identified by
depicting, for each study file, the inverse of the median standard error of the beta estimates
across all SNPs against the square root of the sample size. The inverse proportionality
between the median standard error and the square root of the sample size derives from the
fact that the sampling variance of a linear regression–derived beta-estimate of a specific
SNP j depends on the variance of the phenotype, Var(Y), the variance of the SNP genotype,
Var(Xj), and the sample size . If the regression model is
adjusted, then Var(Y) reflects the variance of the residuals. Thus, the average of the standard
errors across all SNPs will reflect the sample size. Assuming that the sample size for a given
SNP is close enough to the maximum sample size for all SNPs, Nj = N,, the median of the
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standard errors across all m SNPs (j=1…m) can be written as
 and therefore
(1)
with . The constant c can be computed per study file incorporating
the genotype frequencies (for genotyped variants) or the genotype dosages and imputation
quality (for imputed variants) and will depend on individuals’ ethnicity, genotyping
platform, imputation reference panel, and imputation quality. Ignoring the uncertainty from
the imputation, c can be approximated by
(2)
However, the computation of c per study is not ideal for comparing the studies with each
other. Differences in the MAF distribution between any individual study and the reference
would not be detected. For several standard platforms, imputation panels and ethnicities,
these approximate c values to be used in the SE-N plot are given in Table 3. For other
platforms, panels or ethnicities, c is to be computed from a reference study or the imputation
reference panel.
The study-specific data points of the SE-N plot will tend to describe a straight line.
However, studies will deviate from the overall trend, if:
i. the study’s phenotypic variance differs from other studies, which might be
explained by a different study design or special study population;
ii. the study’s MAFs differ from other studies, which might be explained by a
diverging genotyping platform, reference panel for the imputation, or a different
ethnicity;
iii. the study’s SNP imputation qualities differ from those of other studies, which
might reflect errors in the imputation or a different reference panel;
iv. the study’s effective sample size differs from the stated sample size, which might
be due to unaccounted relatedness between study participants or mis-coded sample
size;
v. the study analyst has used a different statistical test; or
vi. the study analyst has mis-specified the phenotype transformation or the regression
model, which results in a different phenotype variance or residual variance (see
Figure 2, Anticipated Results, Supplementary Figure 2).
The P-Z plot (Steps 21–22): Analytical problems related to the study-specific computation
of beta estimates, standard errors or P-values can also be revealed by a study-specific scatter
Winkler et al. Page 10
Nat Protoc. Author manuscript; available in PMC 2014 November 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
plot that, for each SNP, compares the reported P-values with the P-values computed from
the Z-statistics based on reported beta-estimate and standard error (Z statistics = βj/SE (β)j)
(Figure 3, Anticipated Results, Supplementary Figure 3).
The EAF-plot (Steps 23–24): Plotting reported effect allele frequencies (EAF) against a
reference set, such as from the HapMap32 or 1000 Genomes33 projects, or from one specific
study, can help to visualize patterns that pinpoint strand issues, allele miscoding, or the
inclusion of individuals whose self-reported ancestry did not match their genetic ancestry
(Figure 4, Anticipated Results). A strand mismatch or allele miscoding may severely reduce
statistical power. If, for example, a study (or several studies) reports alleles on the ‘−’
instead of ‘+’ strand, which cannot be corrected for ‘palindromic’ A/T or C/G SNPs, a true
signal will be diminished, abolished, or even reversed. Although comparison of allele
frequencies across studies will not detect strand issues or allele miscoding for SNPs with
MAF close to 0.5, this comparison will be informative for most SNPs.
The lambda-N plot (Steps 25–26): Population stratification can either inflate or deflate
association P-values and can be grasped by the genomic control (GC) inflation factor
(λGC)34. As λGC increases with sample size in the case of polygenic phenotypes35, plotting
λGC versus sample size per study file identifies inflated λGC and thus potential problems
with population stratification (Figure 5, Anticipated Results). In the GIANT Consortium,
analysts of studies with λGC >1.1 are contacted and asked to revisit their analyses (e.g.
adjusting for principal components) and results.
Meta-Analysis and QC of meta-analysis output (Steps 27–32)—The meta-analysis
combines the study-specific association results to obtain an overall estimate of the
association and its P-value. The inverse-variance weighted meta-analysis using the fixed-
effects model is most commonly used for GWAMAs (e.g. implemented in METAL36). The
Q statistic and I2 measure test and estimate between-study heterogeneity22,37. For SNPs with
pronounced heterogeneity (I2 > 75%), the effect estimation benefits from a random effects
meta-analysis38. An alternative approach for deriving overall P-values is the sample size-
weighted Z-score meta-analysis39. This approach is used when beta-estimates or standard
errors are not available, or when the meta-analyzed traits are on a different scale (e.g. blood
level data measured in different labs or differences in trait transformation) at the cost of
losing power.
Meta-analyses are conducted by two meta-analysts independently, each uploading the results
and log files on to the server (Supplementary Figure 1). Results are compared using (i) the
log files that specify the study files included and the meta-analysis parameters set in the
software program, (ii) descriptive statistics (min, median, max) of sample size and number
of SNPs included in meta-analysis results, and (iii) correlation and scatter plot of P-values.
Differences between the two analyses are resolved until agreement is reached.
To evaluate whether the statistics of the meta-analyzed effect are inflated due to population
stratification accumulated across studies or due to unaccounted relatedness, the λGC is
computed for the meta-analysis result (complementing the file-specific λGC values, see
above). A high value (λGC >1.1) might be due to (a) an excess of association signals in large
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GWAMAs for highly polygenic traits14, (b) residual population stratification per study file
accumulated across studies, (c) relatedness between individuals across strata, when the
study-specific analyses have been performed separately by strata), or (d) related subjects
across studies, which can more likely occur in very large GWAMAs. In the case of (c), a
meta-analysis across strata per study can be conducted and a study-specific λGC >1.1 might
provide insight into inflation requiring contact of the study analyst. Generally, we
recommend applying the lambda GC correction on the file-level and on the meta-analysis
level (double GC correction), but very large GWAMAs (> 200,000 individuals) on highly
polygenic traits, such as height, may opt to omit the second GC correction (single GC
correction)35.
Finally, when all issues are resolved, one of the analysts shares the final results with the
analysis task group (Supplementary Figure 1). The final results file will be used for all
subsequent steps, including SNP selection for top hit identification and/or follow-up.
Special considerations for custom array data instead of genome-wide SNP
array data—The GIANT consortium has worked on data genotyped using the Metabochip,
a custom genotyping array that contains ~195,000 replication and fine-mapping SNPs
chosen from GWAMAs of metabolic, cardiovascular and anthropometric traits9. Although
many of the QC steps for HapMap imputed SNP data can be directly applied to the
Metabochip and other customized genotype arrays, some steps need to be adjusted, which
are summarized in the following section and given in the protocol as alternative route to
using HapMap imputed SNP data: (i) To control genotype quality instead of imputation
quality, a filter on call rate and deviation from Hardy-Weinberg equilibrium (HWE) is
required; (ii) some genotyped SNPs may not be available in the HapMap reference data,
which requires other references to identify strand and allele frequency errors; and (iii) to
perform GC correction for chips designed to cover multiple traits, the calculation of the λGC
needs to be limited to a subset of SNPs that are chosen from a trait that is uncorrelated with
the trait of interest. This λGC is then to be applied to all SNPs on the array. For example,
GIANT limits the λGC computation for Metabochip data to the 4,427 QT-interval SNPs as
the QT-interval is uncorrelated with the GIANT traits, as recommended by the Metabochip
designers9.
Software—Using the standard, open-source and freely-available software R40 and the
graphical R package ‘Cairo’, we created a pipeline for completing this protocol into a
downloadable GWAMA-QC R package called EasyQC. We provide code application
directly in the procedure steps. The general basic usage is described in Box 2. Minimum
system requirements are described in the Materials.
We provide a number of template scripts that enable to conduct multiple procedure steps at
once: (i) EasyQC scripts ‘1_filelevel_qc.gwa.ecf’ and ‘1_filelevel_qc.metabochip.ecf’ to
perform file-level QC (Steps 7–18); (ii) EasyQC script ‘2_metalevel_qc.ecf’ to perform
meta-level QC (Steps 19–26); (iii) METAL-script ‘3_metaanalysis.metal.txt’ to perform the
meta-analysis (Steps 27–28); (iv) EasyQC script ‘4_metaanalysis_qc.compare.ecf’ to
compare two meta-analysis results for meta-analysis QC (Steps 29–30); (v) R script
‘4_metaanalysis_qc.compare_logfiles.r’ to compare two meta-analysis log-files with regards
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to included and excluded files for meta-analysis QC (Step 30); and (vi) EasyQC script
‘4_metaanalysis_qc.studymeta.ecf’ to perform study-specific meta-analyses for meta-
analysis QC (Steps 31–32).
Parts of the EasyQC template scripts and single EasyQC functions can also be included into
other existing QC pipelines. This task can be accomplished by removing functions from the
scripting interface of the template scripts (see Box 2).
Future studies, like GWAMAs using 1000 Genomes imputed data, will exhibit an increased
number of variants and will include additional genetic structures such as indels or SVs. The
EasyQC software is specifically designed to handle large datasets and can thus be used for
larger SNP panels. With regard to memory requirement, EasyQC requires a minimum of 30
GB random access memory (RAM) for 1000 Genomes imputed data (~40M SNPs) for the
file-level QC, which is the protocol part requiring the largest memory. Alternatively, the
file-level QC steps can be parallelized by splitting the data into smaller parts, e.g. by
chromosome or into overlapping segments of 5Mb, as recommended for 1000 Genomes
imputation. To handle indels and SVs, adjustments to the scripts, like allowing for “I”
(insertion) and “D” (deletion) alleles, are needed and can be made directly to the provided
EasyQC scripts. To this end, the EasyQC package is under active development and future
updates will include scripts tailored to 1000 Genomes data.
MATERIALS
EQUIPMENT
Data—
- Allele frequency reference panels: For HapMap imputed GWAs data: HapMap
CEU frequencies as given in ‘AlleleFreq_HapMap_CEU.v2.txt.gz’. For typed
Metabochip data: 1000 Genomes EUR frequencies as given in
‘AlleleFreq_1000G_EUR_Metabochip.v1.txt.gz’. Both files are available from
the relevant website of the Department of Genetic Epidemiology, University of
Regensburg http://www.genepi-regensburg.de/easyqc/.
- SNP identifier reference panel for marker harmonization: The file
‘SNPID_to_ChrPosID.b36_v2.txt.gz’ (available from the website http://
www.genepi-regensburg.de/easyqc/) maps ~9.1 million known different SNP-
IDs (column “SNPID”, which contains different versions of rs-IDs from b35,
b36 or b37, as well as array-specific marker names like “SNP_1_12345”) to
~4.8 million unique ChrPosIDs (column “ChrPosID”). It can be used to
harmonize SNP identifier names between HapMap imputed or Metabochip data
(see Step 15). It does not include sex-chromosomal SNPs. Please see the
Supplementary Methods for a description of the file creation.
- QT interval SNPs for GC correction of typed Metabochip data and only for traits
that are not correlated with the QT interval: ‘QTSNPs_AEL_TW.txt’ (available
from the website http://www.genepi-regensburg.de/easyqc/).
- Multiple summary-level association result files.
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Software—
- Statistical software R (http://cran.r-project.org/)
- R Package EasyQC (http://www.genepi-regensburg.de/easyqc/);
- Meta-analysis software METAL (http://www.sph.umich.edu/csg/abecasis/
metal/);
- Template R-, EasyQC- and METAL-scripts that can be used to conduct multiple
procedure steps are available from http://www.genepi-regensburg.de/easyqc/
Hardware—
- Computer workstation or server with Unix or Linux operating system
- Minimum memory requirements: For performing the file-level QC (which is the
most memory-intensive step due to evaluating unfiltered data) with HapMap
imputed data (~2.8M SNPs) at least 4GB of random access memory (RAM)
should be available
PROCEDURE
Setting up logistics of meta-analysis (Timing ~2 months)
1. Identify GWAS partners and lay out rules of cooperation (“Memorandum of
understanding”, MOU). Form task groups and set up phone meetings.
2. Develop a GWAS analysis plan (Supplementary Manual), including instructions
on phenotype transformation, analysis models, covariate adjustment,
stratification, use of reference panels for imputation, and formatting of data
submissions.
3. Set up an sftp site that will be used to collect and securely store the data and
organize and label directories and sub-directories in a logical self-explanatory
manner (Supplementary Figure 1).
Collecting aggregated statistics per study (Timing ~2 months)
4. Send out the analysis plan and allow for 2 months for the collaborators to
provide the data.
5. In the meantime, prepare file cleaning instructions and a meta-analysis plan.
6. When all files are available (or at least files from >80% of studies), freeze the
data, i.e. protect the data from further changes (Supplementary Figure 1),and
start conducting the file-level QC.
File-level QC (Timing ~2 months)
Critical—The following file-level QC tasks (Steps 7–18) can be grouped by study and be
assigned to a set of analysts. Check whether format and variable names included in the study
file match the requested format and columns. The following example uses the terminology
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of the GIANT format described in Box 1 and assumes that data is provided by study
collaborators in tabular (TAB) delimited text files with missing values being indicated by ‘.’.
7. To check variable names and format in EasyQC, define the requested columns
and format using the DEFINE and the EASYIN functions in the ecf-header (for
more information on how to use EasyQC, see Box 2) using option A for imputed
data or option B for genotyped Metabochip data.
A. Defining columns and format for imputed data
i. Type the following commands:
DEFINE –-acolIn
MarkerName;Strand;Chr;Pos;N;Effect_allele;Other_
allele;EAF;Information_type;Information;BETA;
SE;P
--acolInClasses
character;character;character;integer;integer;ch
aracter;character;numeric;numeric;numeric;num
eric;numeric;numeric
--strMissing .
--strSeparator TAB
EASYIN --fileIn /path2input/study.gwa.file1.txt
EASYIN --fileIn /path2input/study.gwa.file2.txt
…
B. Defining columns and format for genotyped Metabochip data
i. Type the following commands:
DEFINE -–acolIn
MarkerName;Strand;Chr;Pos;N;Effect_allele;Other_
allele;EAF;P_HWE;Callrate;BETA;SE;P
--acolInClasses
character;character;character;integer;integer;ch
aracter;character;numeric;numeric;numeric;num
eric;numeric;numeric
--strMissing .
--strSeparator TAB
EASYIN --fileIn /path2input/
study.metabochip.file1.txt
EASYIN --fileIn /path2input/
study.metabochip.file2.txt
…
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8. (OPTIONAL) If column names were labeled wrongly, e.g. the analyst used
‘Pvalue’ instead of ‘P’, change the column names centrally, as this is more time-
efficient. If any of the requested columns cannot be clearly allocated or are even
missing, consult the study analyst for clarification or — if needed — ask for re-
upload. EasyQC will only start to iterate over the defined input files if their
headings and format match the requested columns and the requested format.
Minor changes to the requested format, e.g. renaming column names or using a
different delimiter, can be handled by EasyQC directly through small
adjustments in the ecf-header.
?TROUBLESHOOTING
9. Filter monomorphic SNPs. Exclude and count SNPs with allele frequency = 0 or
=1. In EasyQC, this can be done using the ‘CLEAN’ function:
CLEAN --rcdClean (EAF==0)|(EAF==1) --strCleanName numDrop_Monomorph
10. Filter SNPs with missing values. Exclude and count all SNPs with missing
alleles, P-value, beta estimate, standard error, allele frequency or sample size. In
EasyQC, this can be done using the ‘CLEAN’ function:
CLEAN --rcdClean is.na(Effect_allele) --strCleanName 
numDrop_Missing_EA
CLEAN --rcdClean is.na(Other_allele) --strCleanName 
numDrop_Missing_OA
CLEAN --rcdClean is.na(P) --strCleanName numDrop_Missing_P
CLEAN --rcdClean is.na(BETA) --strCleanName numDrop_Missing_BETA
CLEAN --rcdClean is.na(SE) --strCleanName numDrop_Missing_SE
CLEAN --rcdClean is.na(EAF) --strCleanName numDrop_Missing_EAF
CLEAN --rcdClean is.na(N) --strCleanName numDrop_Missing_N
11. Filter SNPs with non-sense values. Exclude and count all SNPs with alleles
other than ‘A’,’C’,’G’ or ‘T’; P-values <0 or >1; negative or infinite standard
errors (<=0 or =Infinity); infinite beta estimates or allele frequencies <0 or >1.
In EasyQC, this can be done using the ‘CLEAN’ function:
CLEAN --rcdClean !(Effect_allele%in%c('A','C','G','T')) --
strCleanName numDrop_invalid_EA
CLEAN --rcdClean !(Other_allele%in%c('A','C','G','T')) --
strCleanName numDrop_invalid_OA
CLEAN --rcdClean P<0|P>1 --strCleanName numDrop_invalid_P
CLEAN --rcdClean SE<=0|SE==Inf --strCleanName numDrop_invalid_SE
CLEAN --rcdClean abs(BETA)==Inf --strCleanName numDrop_invalid_BETA
CLEAN --rcdClean (EAF<0)|(EAF>1) --strCleanName numDrop_invalid_EAF
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12. Filter SNPs on allele frequency and sample size. Exclude and count SNPs with a
sample size <30. Add a column called MAC defined as 2 times sample size
times minor allele frequency and exclude and count all SNPs with MAC<=6. In
EasyQC, these steps can be performed using the following EasyQC code:
CLEAN --rcdClean N<30 --strCleanName numDrop_Nlt30
ADDCOL --rcdAddCol 2*pmin(EAF,1-EAF)*N --colOut MAC
CLEAN --rcdClean MAC<=6 --strCleanName numDrop_MAClet6
13. Filter SNPs on genotype quality. Use option A for imputed data or option B for
genotyped Metabochip data:
A. Filtering SNPs in imputed data
i. Filter SNPs due to non-sense or missingness: Exclude and
count SNPs with missing Information_type, genotyped
SNPs (indicated by Information_type =0) with an
imputation quality less than 1 (Information <1), imputed
SNPs (Information_type !=0) with missing imputation
quality. In EasyQC, this can be done using the ‘CLEAN’
function:
CLEAN --rcdClean is.na(Information_type)
--strCleanName numDrop_MissingInformationType
CLEAN --rcdClean 
Information_type==0&Information<1
--strCleanName numDrop_Genotyped_LowInformation
CLEAN --rcdClean (Information_type!= 
0)&(is.na(Information))
--strCleanName 
numDrop_Imputed_MissingInformation
ii. Filter SNPs on imputation quality: Exclude and count
SNPs with low imputation quality using a threshold that
depends on the imputation and association software used
(Table 2). In EasyQC, this can be done using the
‘CLEAN’ function:
CLEAN
--rcdClean
(Information_type!=0&Information<0.3)|
(Information_type==2&Information<0.4)|
(Informati on_type==3&Information<0.8)
--strCleanName numDrop_LowInformation
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B. Filtering SNPs in genotyped Metabochip data
i. Filter SNPs due to non-sense or missingness: Exclude and
count SNPs with: (1) missing per-SNP callrate; (2)
missing HWE P-values; (3) Callrate or Phwe <0 or >1. In
EasyQC, this can be done using the ‘CLEAN’ function:
CLEAN --rcdClean is.na(Callrate) --strCleanName 
numDrop_MissingCallrate
CLEAN --rcdClean is.na(P_HWE) --strCleanName 
numDrop_MissingPhwe
CLEAN --rcdClean Callrate<0|Callrate>1 --
strCleanName numDrop_InvalidCallrate
CLEAN --rcdClean P_HWE<0|P_HWE>1 --strCleanName 
numDrop_InvalidPhwe
ii. Filter SNPs on low call rate and SNPs violating the HWE:
Exclude and count SNPs with Callrate<0.95 and SNPs
with P_HWE<10−6. In EasyQC, this can be done using
the ‘CLEAN’ function:
CLEAN --rcdClean Callrate<0.95 --strCleanName 
numDrop_LowCallrate
CLEAN --rcdClean P_HWE <1e-6 --strCleanName 
numDrop_LowHwe
14. Filter and count SNPs on sex chromosomes. Keep the sex-chromosomal SNPs in
a separate file for optional subsequent analyses. In EasyQC, this can be done
using the ‘CLEAN’ function:
CLEAN --rcdClean !Chr%in%c(1:22,NA) --strCleanName 
numDropSNP_ChrXY --blnWriteCleaned 1
If the chromosomal information is missing in the input file, all SNPs on the sex
chromosomes will be excluded by the next step.
15. Harmonize SNP identifiers. To maximize the overlap in the number of SNPs
between the study files and to ensure a proper meta-analysis, create a unique
SNP-ID called ChrPosID, which uses the unique format “chr<chr>:<position>”
(e.g. ‘chr10:104207431’, which only uses genetic positions on build 36). We
propose two alternative approaches for this SNP-ID harmonization. Use option
A, for studies that lack information on genetic positions (columns Chr and Pos).
Option A was implemented in GIANT meta-analyses as the genetic positions
were not available in many of the studies (in particular in those that contributed
to earlier rounds of analyses). For future studies, we recommend using option B
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for which Chr and Pos is requested from each collaborator to allow compiling
the ChrPosID from the provided information. Option B is the preferable, more
generic approach that easily handles novel genotyping arrays (e.g. Exomechip),
imputation reference panels (e.g. 1000 Genomes) or genome builds that are not
depicted by the provided reference panel ‘SNPID_to_ChrPosID.b36_v2.txt.gz’
(Supplementary Methods).
A. Creating ChrPosID if genetic positions are not available in the
study file
i. Create a SNP identifier reference panel. Create a
reference file that can be used to remap different versions
of SNP names to unique ChrPosIDs (see Supplementary
Methods for detailed descriptions on how-to create such a
reference file). In case of analyzing HapMap imputed or
Metabochip data on genome build 36, use the provided
SNP identifier reference panel
‘SNPID_to_ChrPosID.b36_v2.txt.gz’ (Supplementary
Methods).
ii. Add the unique ChrPosID to the study file by merging the
study file column MarkerName with the reference file
column SNPID. In EasyQC, this can be done using the
‘RENAMEMARKER’ function:
RENAMEMARKER --colInMarker MarkerName
--fileRename /path2reffiles/
SNPID_to_ChrPosID.b36_v2.txt.gz
--colRenameOldMarker SNPID
--colRenameNewMarker ChrPosID
iii. Check the format of existing ChrPosIDs. To avoid
formatting errors with existing ChrPosIDs in study files,
remove all spaces from the SNP names (i.e. transform
‘chr10 : 104207431’ to ‘chr10:104207431’) and add the
character string ‘chr’ at the beginning of the SNP name in
case it was forgotten (i.e. transform ‘10:104207431’ to
‘chr10:104207431’). In EasyQC correcting the format of
mislabeled ChrPosID SNPs can be performed using the
following commands:
EDITCOL --rcdEditCol gsub(" ","", ChrPosID) --
colEdit ChrPosID
EDITCOL --rcdEditCol 
ifelse(regexpr(":",ChrPosID)==2 | 
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regexpr(":",ChrPosID)==3,
paste("chr", ChrPosID,sep=""), ChrPosID)
--colEdit ChrPosID
B. Creating ChrPosID if genetic positions are available in the study
file
i. Generate ChrPosID directly from the provided Chr and
Pos columns by horizontally concatenating the string
“chr”, column Chr, character “:” and column Pos. This
approach requires genetic positions to be given in the
study file. In EasyQC, this can be done using the
‘ADDCOL’ function:
ADDCOL --rcdAddCol 
paste(“chr”,Chr,”:”,Pos,sep=””) --colOut 
ChrPosID
16. Filter duplicate SNPs. To use the best candidate, exclude the duplicate with the
smaller sample size. In EasyQC, this can be done using the
‘CLEANDUPLICATES’ function:
CLEANDUPLICATES --colInMarker ChrPosID --strMode samplesize --colN 
N
17. Save cleaned files: Add the prefix “CLEANED.” to the filename, save the
cleaned file and use ‘.’ as missing character. In EasyQC, this can be done using
the ‘WRITE’ function:
WRITE --strPrefix CLEANED. -–strMissing . -–strMode gz
18. To perform a file-level QC check, prepare a summary for each study file: Count
and check the number of SNPs in the cleaned file and the number of exclusions
for each procedure step. An example list of report variables is given in
Supplementary Table 1. The number of SNPs in the cleaned file should be >2.2
million for GWAS data (if imputed to a HapMap II reference panel) and
>100,000 for Metabochip data. Major departures from these expected values,
generally large numbers of exclusions or any exclusions due to missing or
nonsense values (Steps 10, 11, 13Ai, 13Bi) may indicate systematic issues with
the file; consult the study analyst to clarify. When using EasyQC, open the
generated summary report in Excel. The report is automatically written to the
output path and carries the file extension ‘.rep’. It contains one row per input file
and the QC variables - to be checked - in columns (Supplementary Table 1).
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Meta-level QC (Timing ~2 months)
19. Identify analytical issues by the SE-N plot. To check for issues with trait-
transformation, the coded sample-size or file-naming, calculate the median
standard error and maximum sample size of every input and produce a plot of c/
median(SE) versus Sqrt(max(N)) (one point for each file, Figure 2). The
proportionality constant c depends on the genotyping platform or the imputation
reference panel (Table 3). Find values for c for standard platforms and panels in
Table 3, i.e. use 1.93 for typed Metabochip data or 1.75 for HapMap II imputed
GWAS data. For platforms or panels other than those given in Table 3, the value
of c needs to be computed de novo by Equation (2) for one study with the
respective platform or for the imputation reference panel; this c can then be
applied to the other studies. In EasyQC, calculate the statistics and create the
plot using the ‘CALCULATE’ and ‘RPLOT’ functions:
CALCULATE --rcdCalc max(N,na.rm=T) --strCalcName Nmax
CALCULATE --rcdCalc median(SE,na.rm=T) --strCalcName SEmedian
RPLOT --rcdRPlotX sqrt(Nmax)
--rcdRPlotY [c]/SEmedian
--rcdRPlotY [c]/SEmedian
--arcdAdd2Plot abline(a=0,b=1,col="orange")
--strAxes zeroequal
--strPlotName SEN-PLOT
# Please replace [c] at --rcdRPlotY with the respective value from 
Table 3.
20. Check whether the points follow the identity line. In case any points clearly
deviate from the diagonal, consult study analyst to clarify trait transformation,
sample-size coding and file-naming (Figure 2, Anticipated Results). Studies
with unaccounted relatives show deviation from the identity line as the effective
sample size is different from the actual sample size, but whether unaccounted
relatedness is the reason for an observed deviation should be confirmed after
consultation with the analyst.
21. Identify analytical issues by the P-Z scatter plot. To check for problems with
beta estimates, standard errors and P-values, create plots comparing P-values (on
the −log10 scale) calculated from a Z statistic (Z=β/SE(β)) with the P-values
directly provided by study partners. (Figure 3, Supplementary Figure 3). In
EasyQC, this can be done using the ‘PZPLOT’ function:
PZPLOT --colBeta BETA --colSe SE --colPval P
22. Check whether the points follow the identity line. In case any points clearly
deviate from the diagonal, consult study analyst (Figure 3, Anticipated Results).
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23. Identify problems with allele frequencies or strand. To check for strand and
allele frequency issues, plot the allele frequency of each SNP and for each file
against a reference allele frequency (one plot for each file) (Figure 4,
Supplementary Figure 4). For HapMap imputed GWAS data, plot allele
frequencies against publically available HapMap allele frequencies, which are
reported in the reference file ‘AlleleFreq_HapMap_CEU.v2.txt.gz’. For
genotyped Metabochip data, plot allele frequencies against publically available
1000 Genomes allele frequencies, which are reported in the reference file
‘AlleleFreq_1000G_EUR_Metabochip.v1.txt.gz’. In EasyQC, the AFCHECK
function can be used to create these plots (please replace [reffile] in the
following code with the respective reference file name):
AFCHECK --colInMarker ChrPosID
--colInStrand Strand
--colInA1 Effect_allele
--colInA2 Other_allele
--colInFreq EAF
--fileRef /path2reffiles/[reffile]
--colRefMarker ChrPosID
--colRefA1 A1
--colRefA2 A2
--colRefFreq Freq1
--blnMetalUseStrand 1
# Replace the path to the reference and the reference-file name at 
--fileRef
24. The frequencies should be distributed along the identity line. Check whether
there are patterns (see Figure 4, Anticipated Results) that indicate problems with
strand or allele frequencies. In case you observe such patterns, contact study
analyst to clarify the issue. To define the problem more precisely, it can be
helpful to provide the collaborator with a list of (i) outlying SNPs, i.e. SNPs
with allele frequencies that deviate >20% from the reference population, and (ii)
mismatching SNPs, i.e. SNPs with alleles that do not match the reference, e.g.
AC in study versus AT in reference population. The AFCHECK function
automatically saves the lists of outlying or mismatching SNPs to the output path
(files indicated by suffix ‘AFCHECK.outlier.txt’ and
‘AFCHECK.mismatch.txt’). In case of problems, it can also be helpful to check
the summary report variables indicated by ‘AFCHECK.[variablename]’
(Supplementary Table 2).
25. Identify population stratification. Calculate λGC for each study file – without
applying the GC correction at this stage – using all SNPs for imputed GWAS
data, and, for custom chip data, only a subset of SNPs that are not associated
with the outcome of interest. In GIANT, 4,425 QT-interval SNPs (defined in
‘QTSNPS_AEL_TW.txt’) were used to derive the λGC for typed Metabochip
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data. To get an overview of the λGC values across all studies and to identify
studies with high λGC, produce a plot of λGC values versus the maximum sample
sizes (Figure 5). In EasyQC, the calculation of the λGC and the plotting can be
done using the ‘GC’ and the ‘RPLOT’ function:
GC --colPval P
--blnSuppressCorrection 1
# --fileGcSnps /path2reffiles/QTSNPs_AEL_TW.txt
# --colInMarker ChrPosID
# --colGcSnpsMarker ChrPosID
# Uncomment last three parameters for Metabochip data
RPLOT --rcdRPlotX Nmax
--rcdRPlotY Lambda.P.GC
--arcdAdd2Plot abline(h=1,col='orange');abline(h=1.1,col='red')
--strAxes lim(0,NULL,0,NULL)
--strPlotName GC-PLOT
26. Examine the plot and check whether λGC is above 1.1 in any of the individual
studies. If this is the case, go back to the relevant study analyst to clarify
potential issues with population stratification, unaccounted relatedness or
duplicated samples included in the analyses (Figure 5, Anticipated Results). The
summary report table created by EasyQC might be helpful to identify studies
that exhibit high λGC (variable GC.P.Lambda, Supplementary Table 2).
Meta-analysis (Timing ~0.5 months)
27. Prepare scripts for an inverse variance-weighted meta-analysis using a fixed
effects model with METAL, as follows: For quality control, we recommend that
two analysts perform the meta-analysis independently. The two analysts should
ensure that the order in which the studies are read into METAL is the same,
because the first study defines the allele coding directions and the following
studies are compared with this study. We advise to run METAL using the
following column definitions and options in the METAL script:
# Input columns: MARKER ChrPosID
ALLELE Effect_allele Other_allele
EFFECT BETA
STDERRLABEL SE
FREQLABEL EAF
PVALUE P
STRAND Strand
CUSTOMVARIABLE N
LABEL N AS N
# Metal Options:
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SCHEME STDERR
WEIGHT N
USESTRAND ON
AVERAGEFREQ ON
MINMAXFREQ ON
VERBOSE OFF
GENOMICCONTROL ON
# GENOMICCONTROL LIST /path2reffiles/QTSNPs_AEL_TW.txt
# Use the latter for metabochip data!
PROCESS /path2cleanedfiles/CLEANED.study1.file1.txt.gz
PROCESS /path2cleanedfiles/CLEANED.study1.file2.txt.gz
# …
PROCESS /path2cleanedfiles/CLEANED.study1.fileM.txt.gz
PROCESS /path2cleanedfiles/CLEANED.study2.file1.txt.gz
# …
PROCESS /path2cleanedfiles/CLEANED.studyN.fileM.txt.gz
OUTFILE metalout .TBL
ANALYZE HETEROGENEITY
To correct for file-specific population stratification, ‘GENOMICCONTROL’
should be set to ‘ON’, as this will apply GC correction to each study file. For
Metabochip studies, the ‘GENOMICCONTROL LIST’ parameter can be used to
limit the calculation of the λGC to the subset of QT-interval SNPs. An alternative
to using METAL for the GC correction by study-file during the meta-analysis is
provided by the EasyQC function ‘GC’ (see the EasyQC manual provided on the
EasyQC website for further details). Implementation of this function can be
added to the file-level QC to correct study-specific standard errors and P-Values
in the same way METAL does. To add metrics that measure between-study
heterogeneity use the command ‘ANALYZE HETEROGENEITY’ at the end of
the METAL script file. We provide template METAL scripts, which include the
described options and commands (‘3_metaanalysis.metal’).
28. Perform the inverse variance-weighted meta-analysis and create a METAL log-
file by using the following command from the command line:
metal 3_metaanalysis.metal > metalout _log.txt
Meta-analysis QC (Timing ~ 1.5 months)
29. Compare results from two meta-analysts. For each of the two meta-analysis
results, calculate descriptive statistics of P-values and sample sizes (length,
number of missing values, minimum, maximum, median, mean and standard
deviation) and the meta-level λGC (again, restrict calculation of the λGC to QT-
interval SNPs for Metabochip results) and check the values for discrepancies. To
compare the meta-analyzed P-values directly, merge the two data sets, create a
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scatter-plot of P-values (on the -log10 scale) and calculate their Spearman
correlation coefficient. In EasyQC, the calculation of the statistics as well as the
merging of the data sets and the creation of the plot, can be done using the
following ‘EasyQC’ code:
DEFINE --acolIn MarkerName;P.value;N
--acolInClasses character;numeric;numeric
EASYIN --fileIn /path2metalresults/metalout.analyst1.TBL --
fileInTag A1
EASYIN --fileIn /path2metalresults/metalout.analyst1.TBL --
fileInTag A2
START EASYQC
EVALSTAT --colStat P.value
EVALSTAT --colStat N
GC --colPval P.value
--blnSuppressCorrection 1
#--fileGcSnps /path2reffiles/QTSNPs_AEL_TW.txt
#--colInMarker MarkerName
#--colGcSnpsMarker ChrPosID
# Uncomment last three parameters for metabochip data
MERGEEASYIN --colInMarker MarkerName
CALCULATE --rcdCalc 
cor(P.value.A1,P.value.A2,method="spearman",use="pairwise.complete.
obs")
--strCalcName corr_Pvals
SPLOT --rcdSPlotX -log10(P.value.A1)
--rcdSPlotY -log10(P.value.A2)
--arcdAdd2Plot abline(a=0,b=1,col='orange')
STOP EASYQC
The summary report table created by EasyQC contains the descriptive values,
the λGC as well as the correlation coefficient (Supplementary Table 3).
30. Examine the calculated values and the scatter plot to check for discrepancies
between the two meta-analysis results. All summary statistics should be
identical and the P-values should lie on the identity line. Most discrepancies
observed between meta-analysts are usually explained by different file
inclusions in the meta-analysis. To get a quick overview on the files included in
the meta-analysis of each analyst, run the R-script
‘4_metaanalysis_qc.compare_logfiles.r’. This action takes the two meta-
analysis log-files as inputs and creates a table that can be used to compare file
inclusions.
31. (OPTIONAL) Identify analytical issues by calculating the study-levelλGC. if
the verified and agreed-on meta-analysis result displays a large meta-level λGC
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(>1.1, check the λGC calculated by step 29), conduct one meta-analysis for each
study (e.g. pooling strata-specific files per study) and calculate the study-level
λGC. An inflated study-level λGC might pinpoint unaccounted relatedness or
overlap of samples across the strata of the study; it can also pinpoint errors as
simple as mis-naming the strata files (e.g. one file is labeled as men, the other as
women, but the men-file was uploaded twice). A substantial fraction of the
inflated meta-level λGC might be explained by such study-specific issues. In
EasyQC, the study-specific meta-analysis as well as the calculation of the study-
level λGC can be performed using the following EasyQC code:
DEFINE --acolIn ChrPosID;Effect_allele;Other_allele;BETA;SE
--acolInClasses character;character;character;numeric;numeric
EASYIN --fileIn /path2cleanedfiles/CLEANED.study1.file1.txt --
fileInTag 1
EASYIN --fileIn /path2cleanedfiles/CLEANED.study1.file2.txt --
fileInTag 2
START EASYQC
MERGEEASYIN --colInMarker ChrPosID
METAANALYSIS --acolBETAs BETA.1;BETA.2
--acolSEs SE.1;SE.2
--acolA1s Effect_allele.1;Effect_allele.2
--acolA2s Other_allele.1;Other_allele.2
--colOutBeta betaPooled
--colOutSe sePooled
--colOutP pPooled
GC --colPval pPooled
--blnSuppressCorrection 1
#--fileGcSnps /path2reffiles/QTSNPs_AEL_TW.txt
#--colInMarker ChrPosID
#--colGcSnpsMarker ChrPosID
# Uncomment last three parameters for metabochip data
STOP EASYQC
The summary report table created by EasyQC contains the study-level λGC.
32. Check the study-level λGC and consult the relevant study analyst in case of a
study-level λGC >1.1. If the study analyst then flags analytical errors, re-analysis
of the study data is needed and steps 7 – 32 have to be repeated for the affected
files.
33. Finalize the meta-analysis. After passing all meta-analysis quality checks,
upload the final meta-analysis results file to the ftp site and freeze the upload
directory (Supplementary Figure 1). Use the agreed-on result files to extract
significant SNPs, to create plots, e.g. Manhattan- or QQ-plots, and for further
evaluation. If a replication of the findings using independent follow-up data is
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planned, all steps of the Procedure can be repeated for the follow-up meta-
analysis.
TROUBLESHOOTING
Step 8: It is likely that data from some studies may have been uploaded in a format that
differs from the requested one. If the format of an input file does not match the requested
format, EasyQC stops with an error message before it starts to iterate over all input files.
Issues such as completely missing columns may require contacting the study analyst. Some
obvious problems, such as different column names (e.g. ‘Pvalue’ instead of ‘P’), different
column separators (e.g. ‘,’ instead of TAB) or missing characters (e.g. ‘NaN’ instead of ‘.’)
can instead be fixed by EasyQC directly (by overwriting the DEFINE parameters at the
respective EASYIN statement):
EASYIN --fileIn /home/fileWithDifferentFormat.txt
–-acolIn
MarkerName;Strand;Chr;Pos;N;Effect_allele;Other_allele;EAF;Information_type;I
nformation;BE
TA;SE;Pvalue
--acolInClasses
character;character;character;integer;integer;character;character;numeric;num
eric;numeric; numeric;numeric;numeric
–-acolNewName
MarkerName;Strand;Chr;Pos;N;Effect_allele;Other_allele;EAF;Information_type;I
nformation;BE
TA;SE;P
--strMissing NaN
--strSeparator COMMA
TIMING
The timing of the whole QC and GWAMA pipeline depends on the number of studies
involved and also on the experience of the analysts. The estimates reported below are based
on the assumption that an existing pipeline of QC and meta-analysis is available (as given by
this protocol). The original GIANT conduct and QC has taken longer due to the exploratory
nature of the effort. The estimates provided are realistic as they are given by experienced
meta-analysts. For a consortium of comparable size to GIANT’s, we estimate the timing of
each procedure step to be as follows:
Steps 1–3, Setting up logistics of meta-analysis: ~2 months
Steps 4–6, Collecting aggregated statistics per study: ~2 months
Steps 7–18, File-level QC: ~2 months
Steps 19–26, Meta-level QC: ~2 months
Steps 27–28, Meta-analysis: ~0.5 months
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Steps 29–32, Meta-analysis QC: ~1.5 months
ANTICIPATED RESULTS
Meta-level QC - Identification of analytical issues by the SE-N plot (Steps 19–20)
In the case of an inverse normal transformed phenotype, forcing the phenotype into the
Standard Normal distribution, N(0,1), the data points on the SE-N plot should tend to
describe a straight line on the diagonal, the identity line. Figure 2a illustrates a major
deviation of a cluster of GIANT studies from the identity for HIPadjBMI in the initial round
of meta-level QC.
To investigate the reason for this deviation, we surveyed the way each study analyst
performed the phenotype transformation. Whether the analyst adjusted the phenotype for
age, age2, study-specific covariates, and BMI by sex according to the analysis plan and then
subjected to the inverse Normal transformation, again separately by sex. This survey
revealed that the studies in the cluster above the identity line first (instead of last) applied
the inverse Normal transformation and then adjusted the phenotype for the covariates; a few
studies had done the adjustment and/or transformation in men and women combined
(instead of by sex), and separated the data by sex afterwards.
Subsequent explorations revealed that the SE-N plot identified this problem for phenotypes
adjusted for BMI (such as HIPadjBMI), but not the BMI-unadjusted phenotypes, since the
adjustment for BMI after the inverse Normal transformation had disrupted the N(0,1)
distribution of the phenotype (Supplementary Figure 2a). Further explorations revealed that
such type of trait transformation issue would result in a loss of power (QQ-plot,
Supplementary Figure 2b) and in estimates biased towards the null (Supplementary Figure
2c).
Other transformation errors that we were able to identify using the SE-N plot (not shown)
include (i) lack of inverse Normal transformation, (ii) the stratification by sex conducted
after the adjustment and inverse Normal transform, (iii) miscoded sample size (e.g. stating
full sample size rather than the sample size used for the analysis).
Meta-level QC - Identification of analytical issues by the P-Z scatter plot (Steps 21–22)
Occasionally, for a large proportion of SNPs, we observed a discrepancy between the P-
value reported by an analysis software and the P-value calculated manually from the Z
statistic based on the reported beta estimates and standard errors (Z=β/SE(β)). In the GIANT
Consortium, we observed such discrepancies caused by the “--score” option in the SNPtest
software. The P-Z plots can detect such issues (Figure 3a) and asking study analyst to re-
analyze the data, using the requested and (in our case) correct “--expected” option, resolved
these issues (Figure 3b). Panels of such plots for each file in the meta-analysis can provide a
quick overview across files and studies (Supplementary Figure 3).
Meta-level QC - Identification of problems with allele-frequencies or strand (Steps 23– 24)
Heterogeneity in allelic patterns may be observed when study allele frequencies are plotted
against a reference set, whether derived from HapMap, 1000 Genomes, or the meta-analysis
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mean allele frequency. Figure 4 shows patterns observed in data submitted to the GIANT
Consortium. Deviations from the reference frequencies are expected for studies of different
ancestry and for studies that have incorrectly coded effect alleles, allele frequencies or
strand. Creating a panel displaying such plots for each study-file at once provides a quick
overview and can identify studies with any of the above issues (Supplementary Figure 4).
Meta-level QC - Identification of population stratification (Steps 25–26)
To detect studies with population substructure, the file-specific λGC versus the square root of
the sample size can be plotted (Figure 5). Study analysts with λGC >1.1 should be contacted
asking them for re-analysis, e.g. including principal components in their analysis model. The
EasyQC report may be of help to identify which studies exhibit a high λGC (Supplementary
Table 2).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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BOX 1 – Study-specific GWAS results – Columns as requested by GIANT
Stated are the columns requested by GIANT from the study partners for each GWAS to
ensure uniform study-specific files:
“MarkerName” – character string; the SNP identifier of the marker analyzed.
“Strand” – a single character “−“ or “+”; Strand on which the allelles are reported.
“Chr” – character; Chromosome.
“Pos” – integer; Base position of the SNP.
“N” – positive integer; The effective number of subjects analyzed.
“Effect_allele” – a single upper case character “A”, “C”, “G”, or “T”; The allele
associated with phenotypic traits (corresponding to change in beta estimates).
“Other_allele” – a single upper-case character "A" "C" "G" or "T"; Indicating the
other (non-effect) allele.
“EAF” – numeric; Effect allele frequency (range 0–1).
“BETA” – numeric; Estimate of the effect size.
“SE” – numeric; Estimated standard error on the estimate of the effect size.
“P” – numeric; Significance of the variant association, uncorrected for genomic
control.
Only for genotyped data:
“P_HWE” – numeric; Exact HWE P-value for the sample analyzed.
“Callrate” – numeric; Call rate for this SNP across all subjects. Perfectly genotyped
(100%) data will have a Callrate = 1.000.
Only for imputed data:
“Information_type” – integer; Code indicating the type of data in the “Information”
column (i.e. the type of the imputation and analysis software used):
0 if the SNP was not tested using imputation/genotyping uncertainty, in which
case the following column “Information” should be missing (e.g. for directly
genotyped SNPs);
1 for a MACH imputed SNP, whereas the following column “Information”
either contains “r2_Hat” from MACH2DAT/MACH2QTL OR “INFO” from
PLINK (in case you have used PLINK for the association with MACH imputed
SNP data)
2 if the following column “Information” contains “proper_info” from
SNPTEST;
3 for a PLINK imputed SNP, i.e. the following column “Information” contains
“INFO” from PLINK (in case the SNP was imputed using PLINK as well)
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4 if the following “Information” column contains “rSqHat” from QUICKTEST.
“Information” – numeric; A value (range 0–1; PLINK values can exceed 1)
corresponding to the information content output from the association testing (according
to the data type specified in the "InformationType" column above).
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BOX 2 - Easy QC programming
Generally EasyQC is started by calling the EasyQC function at the R-prompt and with an
ecf-file as parameter:
> library(EasyQC)
> EasyQC(“/path2ecffile/examplescript.ecf”)
Every data input/output (I/O) and the conducted pipeline is defined in the ecf-file.
EasyQC’s ecf-files are modularized and each step can be conducted separately. An ecf-
file consists of two parts: (i) a header or config-section at the beginning that defines data
I/O using the DEFINE and EASYIN functions; followed by (ii) a scripting interface
which defines the QC steps being executed.
Structure of an ecf-file:
Header to define I/O:
[DEFINE, EASYIN]
Scripting interface with EasyQC function steps:
[CLEAN,GETNUM,ADDCOL …]
Several example scripts and templates that combine multiple steps described in this
protocol are available from our website http://www.genepi-regensburg.de/easyqc/.
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Figure 1. Workflow of the QC and the meta-analysis
A typical GWAMA includes four major stages: (i) The File-level QC (Steps 7–18) includes
the QC of each study file to ensure validity. This stage involves file cleaning (e.g.
adjustments of column headings, file format changes, SNP exclusions based on certain
criteria, or adding columns) and file checks (e.g. checking overall characteristics of the file
or the number of SNP exclusions), usually in an iterative fashion. Typically this task is
divided by study among analysts of the meta-analysis team. Files that pass the file-level QC
are labeled as “CLEANED”. Any issues observed with particular files should be clarified
with the respective study analyst directly. (ii) The Meta-level QC (Steps 19–26) addresses
the comparison of file-specific statistics across files in order to depict study-specific issues
yet undetected. In case issues of specific studies cannot be resolved centrally, the relevant
study analyst should be contacted for clarification.. (iii) Meta-analysis (Steps 27–28) is the
stage at which the meta-analysis is actually conducted, a task typically performed by two
analysts independently. (iv) Meta-analysis QC (Steps 29–32) involves the checking the
meta-analysis results and includes the comparison of the two meta-analyses performed by
the different analysts and the quality control of the meta-analysis result.
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Figure 2. SE-N plots to reveal issues with trait transformations
SE-N plots to detect issues with trait transformations contrasting the study-specific standard
errors with sample sizes for GIANT studies typed on Metabochip and tested for association
with HIPadjBMI (N=81,000): (a) before QC: a number of studies (in fact the majority of
studies) revealed errors by clustering above the identity line, and (b) after QC: the same plot
after having gone back to the relevant study analysts and having resolved all trait
transformation issues. Different colors for the points in the plot indicate men-specific (blue),
women-specific (red) or sex-combined (black) association results.
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Figure 3. P-Z plot to reveal analytical issues with beta, standard error and P-values
Plots to reveal issues with beta estimates, standard errors and P-values for (a) an uncleaned
study file showing severe deviations from the identity line and (b) the cleaned dataset
showing perfect concordance. The plots compare P-values reported in the association result
file to P-values calculated from Z statistics derived from the reported beta and standard error
from an example GIANT file. The uncleaned study file contained a large number of highly
significant but erroneous (reported) P values.
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Figure 4. Different patterns of allele frequencies in the EAF plot
These different patterns have been observed during the QC checks performed by the GIANT
analysts. In the graphs the observed (study-specific) allele frequencies reported on the y-axis
are plotted against the expected (HapMap or 1000 Genomes) allele frequencies, reported on
the x-axis. The plots (a)– (c) represent data from studies where allele frequencies and strand
annotation are correct but participants exhibit different ancestries compared to the reference,
which includes mostly samples of European ancestry: (a) study in which data are relatively
consistent with the reference; (b) study in which participants had slightly different ancestry
to the reference, resulting in a thicker band across the diagonal; (c) study involving
Winkler et al. Page 38
Nat Protoc. Author manuscript; available in PMC 2014 November 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
participants of non-European ancestry resulting in substantial deviation from the reference.
Plots (d)–(h) pertain to studies with errors in coding the effect allele, the effect allele
frequency, and/or strand annotation: (d) a study in which the wrong allele was consistently
labeled as effect allele; (e) a study in which a fraction of the effect alleles was mis-specified,
e.g. from stating the MAF instead of the effect allele frequency, or from incorrectly
assigning strand due to data management or wrong strand reference (sometimes specific to
“palindromic” SNPs A/T or C/G); (f)–(h) all represent studies with other data management
or analytical errors in calculating the allele frequencies.
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Figure 5. Lambda-N plot to reveal issues with population stratification
Plot to detect issues with population stratification contrasting the study-specific λGCwith
sample sizes for GIANT studies typed on Metabochip and tested for association with
HIPadjBMI (N=81,000): (a) before QC: a number of studies displayed high λGC values, and
(b) after QC: the same plot after having gone back to study analyst and having resolved all
issues. The orange line indicates the optimal λGC=1. Dots above the red line, which
visualizes the threshold λGC=1.1, represent problematic studies.
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Table 3
SE-N Plot calibration factors for various genotyping platforms, imputation reference panels, and ethnicities.
Genotyping
Platform
Imputation
reference panel Ethnicity
Calibration
factor (c)
GWAS chip HapMap CEU 1.75
GWAS chip HapMap YRI 1.83
GWAS chip 1000 Genomes ALL 8.86
Metabochip - EUR 1.93
Metabochip - AFR 2.18
The calibration factors were estimated from the publically available HapMap and 1000 Genomes reference data. Only autosomal and non-
monomorphic SNPs were used in the estimation. The Metabochip c factors were estimated from 179,000 overlapping SNPs from 1000 Genomes
reference data frequencies.
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